Corvus Pharmaceuticals, Inc. (CRVS) financial statements (2021 and earlier)

Company profile

Business Address 863 MITTEN ROAD
BURLINGAME, CA 94010
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:44515969788697
Cash and cash equivalents162321235930
Other undisclosed cash, cash equivalents, and short-term investments28283945737767
Prepaid expense0010000
Other current assets0001011
Other undisclosed current assets0001110
Total current assets:45536170798898
Noncurrent Assets
Operating lease, right-of-use asset2222223
Property, plant and equipment1111122
Long-term investments and receivables37      
Long-term investments37      
Other noncurrent assets0011111
Total noncurrent assets:40344455
TOTAL ASSETS:865664748492103
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6656444
Accounts payable3333223
Accrued liabilities0111000
Employee-related liabilities2222221
Debt 111111
Other undisclosed current liabilities6555545
Total current liabilities:12121212101011
Noncurrent Liabilities
Long-term debt and lease obligation1222233
Operating lease, liability1222233
Other undisclosed noncurrent liabilities(1)      
Total noncurrent liabilities: 222233
Total liabilities:13141314131213
Stockholders' equity
Stockholders' equity attributable to parent72425160718090
Common stock0000000
Additional paid in capital295293291290288286285
Accumulated other comprehensive income0000000
Accumulated deficit(223)(250)(241)(230)(217)(206)(195)
Total stockholders' equity:72425160718090
TOTAL LIABILITIES AND EQUITY:865664748492103

Income statement (P&L) ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Operating expenses(10)(10)(11)(13)(11)(12)(14)
Operating loss:(10)(10)(11)(13)(11)(12)(14)
Other undisclosed income from continuing operations before equity method investments, income taxes37      
Income (loss) from continuing operations before equity method investments, income taxes:28(10)(11)(13)(11)(12)(14)
Other undisclosed income from continuing operations before income taxes0   2  
Income (loss) before gain (loss) on sale of properties:28(10)(11)(13)(9)(12)(14)
Other undisclosed net income (loss)(1)  0(2)  
Net income (loss):27(10)(11)(13)(11)(12)(14)
Other undisclosed net income attributable to parent 00  11
Net income (loss) available to common stockholders, diluted:27(10)(11)(13)(11)(11)(13)

Comprehensive Income ($ in millions)

12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
3/31/2020
Q1
12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
Net income (loss):27(10)(11)(13)(11)(12)(14)
Comprehensive income (loss):27(10)(11)(13)(11)(12)(14)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent(0)000(0)11
Comprehensive income (loss), net of tax, attributable to parent:27(10)(11)(13)(11)(11)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: